Eritropoietina: Profilo biologico ed impiego terapeutico

Translated title of the contribution: Erythropoietin: Biological profile and therapeutic use

M. Cazzola, P. Cerani, S. Ferrillo, A. Rovati, A. Vercelli, E. Ascari

Research output: Contribution to journalArticle

Abstract

Erythropoietin is mainly a survival factor for human erythroid progenitor cells. Administration of recombinant human erythropoietin (rHuEpo) is particularly effective in increasing the output of red cells in patients whose endogenous erythropoietin levels are inappropriately low for the degree of anemia. Recombinant human erythropoietin should routinely be given subcutaneously to maximize its effects. Most patients under rHuEpo treatment develop functional iron deficiency. Iron supplementation should therefore be given to all individuals receiving rHuEpo but those with iron overload. Recombinant human erythropoietin is currently used in clinical practice mainly for treatment of anemia associated with renal failure. In the last few years, however, its use has been approved for other indications, including prevention of anemia in surgical patients or in patients undergoing platinum- based chemotherapy, treatment of anemia of prematurity, of anemia induced by zidovudine therapy in HIV-infected patients, and of anemia induced by chemotherapy of nonmyeloid malignancies. Outside the setting of uremia only a portion of patients can clearly benefit from rHuEpo therapy, so that the use of rHuEpo should be individualized in nonrenal applications.

Original languageItalian
JournalAnnali Italiani di Medicina Interna, Supplement
Volume13
Issue number2
Publication statusPublished - 1998

Fingerprint

Therapeutic Uses
Erythropoietin
Anemia
Iron
Therapeutics
Drug Therapy
Erythroid Precursor Cells
Iron Overload
Zidovudine
Uremia
Platinum
Renal Insufficiency
HIV
Survival

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Cazzola, M., Cerani, P., Ferrillo, S., Rovati, A., Vercelli, A., & Ascari, E. (1998). Eritropoietina: Profilo biologico ed impiego terapeutico. Annali Italiani di Medicina Interna, Supplement, 13(2).

Eritropoietina : Profilo biologico ed impiego terapeutico. / Cazzola, M.; Cerani, P.; Ferrillo, S.; Rovati, A.; Vercelli, A.; Ascari, E.

In: Annali Italiani di Medicina Interna, Supplement, Vol. 13, No. 2, 1998.

Research output: Contribution to journalArticle

Cazzola, M, Cerani, P, Ferrillo, S, Rovati, A, Vercelli, A & Ascari, E 1998, 'Eritropoietina: Profilo biologico ed impiego terapeutico', Annali Italiani di Medicina Interna, Supplement, vol. 13, no. 2.
Cazzola, M. ; Cerani, P. ; Ferrillo, S. ; Rovati, A. ; Vercelli, A. ; Ascari, E. / Eritropoietina : Profilo biologico ed impiego terapeutico. In: Annali Italiani di Medicina Interna, Supplement. 1998 ; Vol. 13, No. 2.
@article{fa0ee885fc4e4df9a961103295a4ee5e,
title = "Eritropoietina: Profilo biologico ed impiego terapeutico",
abstract = "Erythropoietin is mainly a survival factor for human erythroid progenitor cells. Administration of recombinant human erythropoietin (rHuEpo) is particularly effective in increasing the output of red cells in patients whose endogenous erythropoietin levels are inappropriately low for the degree of anemia. Recombinant human erythropoietin should routinely be given subcutaneously to maximize its effects. Most patients under rHuEpo treatment develop functional iron deficiency. Iron supplementation should therefore be given to all individuals receiving rHuEpo but those with iron overload. Recombinant human erythropoietin is currently used in clinical practice mainly for treatment of anemia associated with renal failure. In the last few years, however, its use has been approved for other indications, including prevention of anemia in surgical patients or in patients undergoing platinum- based chemotherapy, treatment of anemia of prematurity, of anemia induced by zidovudine therapy in HIV-infected patients, and of anemia induced by chemotherapy of nonmyeloid malignancies. Outside the setting of uremia only a portion of patients can clearly benefit from rHuEpo therapy, so that the use of rHuEpo should be individualized in nonrenal applications.",
author = "M. Cazzola and P. Cerani and S. Ferrillo and A. Rovati and A. Vercelli and E. Ascari",
year = "1998",
language = "Italian",
volume = "13",
journal = "Annali Italiani di Medicina Interna, Supplement",
issn = "1122-0538",
publisher = "Italian Inner Medicine society",
number = "2",

}

TY - JOUR

T1 - Eritropoietina

T2 - Profilo biologico ed impiego terapeutico

AU - Cazzola, M.

AU - Cerani, P.

AU - Ferrillo, S.

AU - Rovati, A.

AU - Vercelli, A.

AU - Ascari, E.

PY - 1998

Y1 - 1998

N2 - Erythropoietin is mainly a survival factor for human erythroid progenitor cells. Administration of recombinant human erythropoietin (rHuEpo) is particularly effective in increasing the output of red cells in patients whose endogenous erythropoietin levels are inappropriately low for the degree of anemia. Recombinant human erythropoietin should routinely be given subcutaneously to maximize its effects. Most patients under rHuEpo treatment develop functional iron deficiency. Iron supplementation should therefore be given to all individuals receiving rHuEpo but those with iron overload. Recombinant human erythropoietin is currently used in clinical practice mainly for treatment of anemia associated with renal failure. In the last few years, however, its use has been approved for other indications, including prevention of anemia in surgical patients or in patients undergoing platinum- based chemotherapy, treatment of anemia of prematurity, of anemia induced by zidovudine therapy in HIV-infected patients, and of anemia induced by chemotherapy of nonmyeloid malignancies. Outside the setting of uremia only a portion of patients can clearly benefit from rHuEpo therapy, so that the use of rHuEpo should be individualized in nonrenal applications.

AB - Erythropoietin is mainly a survival factor for human erythroid progenitor cells. Administration of recombinant human erythropoietin (rHuEpo) is particularly effective in increasing the output of red cells in patients whose endogenous erythropoietin levels are inappropriately low for the degree of anemia. Recombinant human erythropoietin should routinely be given subcutaneously to maximize its effects. Most patients under rHuEpo treatment develop functional iron deficiency. Iron supplementation should therefore be given to all individuals receiving rHuEpo but those with iron overload. Recombinant human erythropoietin is currently used in clinical practice mainly for treatment of anemia associated with renal failure. In the last few years, however, its use has been approved for other indications, including prevention of anemia in surgical patients or in patients undergoing platinum- based chemotherapy, treatment of anemia of prematurity, of anemia induced by zidovudine therapy in HIV-infected patients, and of anemia induced by chemotherapy of nonmyeloid malignancies. Outside the setting of uremia only a portion of patients can clearly benefit from rHuEpo therapy, so that the use of rHuEpo should be individualized in nonrenal applications.

UR - http://www.scopus.com/inward/record.url?scp=0032231574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032231574&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0032231574

VL - 13

JO - Annali Italiani di Medicina Interna, Supplement

JF - Annali Italiani di Medicina Interna, Supplement

SN - 1122-0538

IS - 2

ER -